Eli Lilly: Another Not-To-Miss Dip

Eli Lilly (LLY) shares declined despite strong Q2 2025 financial results and upgraded guidance, attributed to investor disappointment over its oral GLP-1 drug, Orforglipron, showing lower weight loss efficacy (7.8-12.4%) compared to its injectable Zepbound (20.2%). However, the company's Q2 revenue surged 38% year-over-year, driven by robust sales of Mounjaro and Zepbound, which have long patent lives. The article posits this market reaction is an overcorrection, highlighting Orforglipron's strategic advantages like oral convenience and manufacturing scalability, and notes LLY's current forward non-GAAP P/E of 28.49x is significantly below its five-year average, suggesting an attractive valuation for long-term investors.

Analysis

Eli Lilly's (LLY) recent stock decline presents a clear divergence between short-term sentiment and underlying financial strength. The sell-off was triggered by clinical trial results for its oral GLP-1 candidate, Orforglipron, which demonstrated a 7.8-12.4% weight loss, a figure that met its primary endpoint but proved less effective than the company's own injectable Zepbound (20.2%) and competitor products. This market reaction, however, overshadows an exceptionally strong Q2 2025 performance, where revenues surged 38% year-over-year, driven by powerful growth in its established treatments Mounjaro (+85% YoY) and Zepbound (3.23x increase). The company's fundamentals remain robust, with a non-GAAP operating margin of 44.1% and a 61% YoY increase in non-GAAP EPS. Furthermore, management upgraded its full-year non-GAAP EPS guidance to a range of $21.75-$23.00. The subsequent stock price drop has compressed LLY's forward non-GAAP P/E to 28.49x, a significant discount to its five-year average of 43.58x, suggesting the market is overly penalizing the company for pipeline developments while ignoring the performance and long-term patent protection of its core growth drivers.

Key Decisions for Investors

• The significant stock price correction, driven by sentiment around a single pipeline drug, may present a strategic buying opportunity for investors focused on strong fundamentals and long-term growth.
• Investors should prioritize the performance of core revenue drivers Mounjaro and Zepbound, which exhibit strong growth and long patent runways, over the market's negative reaction to the less-effective, albeit strategically valuable, oral Orforglipron.
• Consider the current forward P/E of 28.49x as an attractive valuation entry point relative to the company's historical average, while remaining cognizant that continued high sensitivity to clinical trial data across the GLP-1 space remains a key risk factor.